NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vita Therapeutics

Vita Therapeutics

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://vitatx.com/

Last Round

Series B

Oct 12, 2022

Total Funding Raised

$66M

Company Overview

Vita Therapeutics is a biotechnology company that develops engineered cellular therapies using induced pluripotent stem cell (iPSC) technology to treat neuromuscular diseases and cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyinduced pluripotent stem celliPSCgene editingCRISPRneuromuscular diseaseregenerative medicineautologous cell therapyhypoimmunogenic cell therapysolid tumor therapybiotech licensingcell engineeringmuscular dystrophy treatmentpreclinical biotechcell manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vita Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Vita Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vita Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 12, 2022
Series AJun 23, 2021
SeedJun 26, 2020
GrantJun 5, 2020
SeedJan 1, 2020

Key People

Founding team and executive leadership

Douglas Falk

Co-founder And Chief Executive Officer

Founding Team

Vita Therapeutics Investors

Notable investors and investment history

Vita Therapeutics investors
InvestorRounds
Abell FoundationSeed
TEDCOSeries B, Seed
Early Light VenturesSeries A
Johns Hopkins Technology VenturesSeries A
SCM LifescienceSeries A
Solve FSHDSeries B
Maryland Stem Cell Research FundGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 10, 2025

    Launched a universal iPSC program for FSHD therapy.

  • Jun 23, 2021

    $32M round led by Cambrian Bio.

Vita Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vita Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vita Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range8
Year Founded2019
Last FundingOct 12, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.